BRUSSELS, Belgium, Oct. 18, 2013 /CNW/ - The Mood Disorders Society of
Canada applauds Prime Minister Stephen Harper and the Government of
Canada for reaching an agreement with the world's largest single
market, the European Union.
CETA represents an incredible opportunity to ensure continued Canadian
research and innovation in medicines that will improve the health of
all Canadians and keep highly skilled research jobs in Canada.
With CETA, the government is taking significant steps to address mood
disorders and mental illness, one of the most debilitating illnesses in
our country, and for that we will all be winners.
The effects of depression are far-reaching. An estimated 10 per cent of
Canadians are living with depression, and two-thirds of these will
leave their doctor's office without an effective solution to what ails
them. More than 45 per cent of seniors living in residential care homes
suffer from depression. Anti-depressants are the leading prescription
drug on the campuses of Canada's colleges and universities. The
increase in the number of Canadians considering suicide and the current
lack of an evidence-based suicide prevention strategy is alarming.
The impacts of depression and other mental illnesses go well beyond how
it affects the lives of those who are living with it and their
families, friends and caregivers.
Mental illness is the leading cause of workplace disability in Canada,
carrying an estimated $51-billion cost to the Canadian economy. From
direct and indirect health-care costs, pressure on the criminal justice
system, child abuse and neglect and lost income and productivity due to
missed time at work, depression is one of the biggest challenges facing
Canada, both financially and socially.
CETA will help create the conditions that will encourage more
pharmaceutical research and development and facilitate the associated
clinical trials that test innovative pharmaceutical and cognitive
therapies and interventions which will help develop effective
interventions and improve the mental health of Canadians.
By strengthening Canada's intellectual property (IP) regime, CETA will
ensure continued innovation in medicines and improve the health of all
Canadians, including those with mental illness. The last time Canada
reformed its IP policy 25 years ago, it sparked a boom in private
sector research and development spending in Canada's pharmaceutical
sector. The rest of the world has evolved since then and Canada must
SOURCE: Mood Disorders Society of Canada
For further information: